Premium
Century Therapeutics Inc (IPSC)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -31,17k | 72,94k | Sale to Issuer | 2,34 | 3,68M | -0,84% |
| 2026-05-04 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -264,00 | 618,02 | Vente | 2,34 | 507,00k | -0,05% |
| 2026-04-01 | Dr. Chad A. CowanChief Scientific Officer | -1,37k | 2,99k | Sale to Issuer | 2,19 | 227,72k | -0,60% |
| 2026-03-12 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -7,04k | 17,95k | Vente | 2,55 | 507,26k | -1,37% |
| 2026-03-12 | Dr. Gregory RussottiChief Technology & Manufacturing Officer | -10,08k | 25,68k | Vente | 2,55 | 608,20k | -1,63% |
| 2026-03-11 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -55,40k | 151,23k | Sale to Issuer | 2,73 | 3,71M | -1,47% |
| 2026-03-11 | Dr. Chad A. CowanChief Scientific Officer | -1,43k | 3,91k | Sale to Issuer | 2,73 | 224,44k | -0,63% |
| 2026-03-09 | Dr. Gregory RussottiChief Technology & Manufacturing Officer | -479,00 | 1,21k | Vente | 2,54 | 379,78k | -0,13% |
| 2026-03-09 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -247,00 | 626,39 | Vente | 2,54 | 297,93k | -0,08% |
| 2026-03-06 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -463,00 | 1,19k | Sale to Issuer | 2,56 | 660,00k | -0,07% |
| 2026-02-13 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -31,17k | 54,55k | Sale to Issuer | 1,75 | 659,38k | -4,51% |
| 2026-02-03 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -323,00 | 588,51 | Vente | 1,82 | 297,30k | -0,11% |
| 2026-01-02 | Dr. Chad A. CowanChief Scientific Officer | -1,61k | 1,60k | Sale to Issuer | 1,00 | 221,00k | -0,72% |
| 2025-12-22 | Dr. Chad A. CowanChief Scientific Officer | 58,06k | 49,25k | Achat | 0,85 | 217,96k | 36,31% |
| 2025-12-12 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | 52,00k | 30,35k | Achat | 0,58 | 617,19k | 9,20% |
| 2025-12-10 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -463,00 | 243,54 | Sale to Issuer | 0,53 | 565,19k | -0,08% |
| 2025-12-08 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -257,00 | 136,72 | Vente | 0,53 | 301,37k | -0,09% |
| 2025-12-08 | Dr. Gregory RussottiChief Technology & Manufacturing Officer | -526,00 | 279,83 | Vente | 0,53 | 350,26k | -0,15% |
| 2025-11-20 | Dr. Chad A. CowanChief Scientific Officer | -5,46k | 2,74k | Vente | 0,50 | 159,90k | -3,30% |
| 2025-11-19 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | 35,00k | 17,33k | Achat | 0,50 | 564,56k | 6,61% |
| 2025-11-17 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -32,46k | 14,74k | Vente | 0,45 | 529,56k | -5,77% |
| 2025-11-03 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -292,00 | 171,11 | Vente | 0,59 | 296,07k | -0,10% |
| 2025-09-08 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -263,00 | 131,50 | Vente | 0,50 | 295,42k | -0,09% |
| 2025-09-08 | Dr. Gregory RussottiChief Technology & Manufacturing Officer | -539,00 | 269,50 | Vente | 0,50 | 349,28k | -0,15% |
| 2025-09-08 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -488,00 | 244,00 | Vente | 0,50 | 488,66k | -0,10% |
| 2025-08-04 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -296,00 | 158,06 | Vente | 0,53 | 294,81k | -0,10% |
| 2025-06-09 | Dr. Gregory RussottiChief Technology & Manufacturing Officer | -526,00 | 327,17 | Vente | 0,62 | 348,32k | -0,15% |
| 2025-06-09 | Dr. Brent PfeiffenbergerPresident, CEO & Chairman | -475,00 | 295,45 | Vente | 0,62 | 341,33k | -0,14% |
| 2025-06-09 | Mr. Douglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary | -4,90k | 3,05k | Vente | 0,62 | 294,17k | -1,64% |
| 2025-06-09 | Dr. Adrienne FaridInitié | -552,00 | 343,34 | Vente | 0,62 | 94,50k | -0,58% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
